Poziotinib’s Shift Of Focus To HER2 May Increase Approval Chances
Potential First-Line Therapy
Encouraging new data for Spectrum/Hanmi’s poziotinib presented at ESMO may increase the chances of approval for the pan-HER inhibitor as a possible first-line therapy for NSCLC with the HER2 exon 20 insertion mutation, although the patient population is limited.
